HIV protease is an enzyme the virus uses to cut large, nonfunctional protein chains into the smaller working parts needed to build infectious copies of itself. Without this single enzyme, HIV can still assemble and bud from a host cell, but the resulting virus particles are structurally immature and completely unable to infect new cells. That makes HIV protease essential for the virus to spread, and it’s one of the primary drug targets in modern HIV treatment.
How HIV Protease Fits Into Viral Replication
When HIV hijacks a human cell, it forces the cell’s machinery to produce long chains of linked proteins called polyproteins. These chains, known as Gag and Gag-Pol, contain all the structural and enzymatic components the virus needs, but they’re fused together in a form that can’t do anything useful. Think of it like a sheet of connected postage stamps: individually they work, but as an uncut sheet they don’t fit on an envelope.
HIV protease is the scissors. It recognizes specific sites along these polyprotein chains and cuts them apart into individual, functional proteins. From the Gag polyprotein alone, protease releases four major components: the matrix protein (which lines the inner membrane of the virus), the capsid protein (which forms the protective shell around the viral genome), the nucleocapsid protein (which coats and stabilizes the RNA), and a small tail-end protein called p6 that helps with budding. From the Gag-Pol chain, protease also frees the enzymes the virus needs for future infections: reverse transcriptase (which converts viral RNA into DNA) and integrase (which inserts that DNA into a host cell’s genome). Protease even cuts itself free from the polyprotein.
When Protease Activates
For years, researchers debated whether protease switched on before or after a new virus particle pinched off from the host cell. Work published in the Journal of Virology settled the question: protease becomes active inside the host cell, during assembly and budding, before the virus particle is fully released. Using high-resolution microscopy and single-particle analysis, researchers showed that the mature form of the enzyme is already working within 15 seconds of a virus particle leaving the cell surface, and that processing begins even earlier, while the particle is still attached to the membrane.
This timing matters. It means maturation is already underway the moment a new virus enters the bloodstream, giving the particle a head start on becoming infectious.
Immature vs. Mature Virus Particles
The difference protease makes is visible under an electron microscope. An immature HIV particle has a thick, spherical shell of uncut protein lining its outer edge. It looks dense and uniform, and it cannot infect anything. Once protease finishes cutting the polyproteins, the freed capsid proteins rearrange themselves into a distinctive cone-shaped core. This conical core holds two copies of the viral RNA genome and gives the mature virus its characteristic shape.
This transformation from a disorganized sphere to a particle with a defined internal core is called maturation. It is not a subtle biochemical footnote. Without it, the virus is dead on arrival. Every single new HIV particle depends on protease completing this job.
The Enzyme’s Structure
HIV protease is relatively small as enzymes go. It’s made of two identical halves, each only 99 amino acids long, that lock together to form the active enzyme. The cutting happens at a pocket in the center where the two halves meet. Two specific amino acids, one from each half, work together to break the bonds in the polyprotein chain. Covering this active site are a pair of flexible flaps that open and close like gates, allowing the protein chain in and releasing the cut pieces.
This compact, symmetrical design is both the enzyme’s strength and its vulnerability. Because the active site is so specific in shape, drugs can be designed to fit snugly inside it and block it from working.
How Protease Inhibitors Exploit This
Every FDA-approved protease inhibitor works the same basic way: it mimics the shape of the protein chain that protease normally cuts, wedges itself into the enzyme’s active site, and stays there. With the active site occupied, the enzyme can’t bind to and process the Gag and Gag-Pol polyproteins. The result is a flood of immature, noninfectious virus particles that can’t complete maturation.
The protease inhibitors currently in clinical use include darunavir and atazanavir, both typically paired with a boosting agent (cobicistat or a low dose of ritonavir) that slows the body’s breakdown of the drug, keeping blood levels high enough to maintain constant pressure on the enzyme. Ritonavir itself was originally developed as a protease inhibitor but is now used almost exclusively in this booster role. One combination pill, Symtuza, packages darunavir with its booster and two other antivirals into a single daily tablet.
Protease inhibitors became available in the mid-1990s and were a turning point in HIV treatment. Adding them to existing drug regimens transformed HIV from a near-certain death sentence into a manageable chronic condition.
Drug Resistance and Why It Develops
HIV replicates sloppily, making frequent copying errors in its genetic material. Some of those random mutations land in the protease gene and change the shape of the enzyme just enough that a drug no longer fits properly into the active site, while the enzyme can still cut its natural targets well enough to function. Over time, especially if drug levels drop too low to fully suppress the virus, these resistant variants outcompete the susceptible ones.
More than 60 mutations have been linked to protease inhibitor resistance, spread across multiple regions of the enzyme. Some occur right in the active site, directly blocking drug binding. Others sit in the flexible flaps that gate access to the pocket, or in interior positions that subtly reshape the enzyme’s overall structure. Mutations at 17 positions carry the greatest clinical significance, with changes at the active site and flap regions causing the most pronounced drops in drug effectiveness.
Resistance to one protease inhibitor often reduces the effectiveness of others, because all approved drugs target the same active site. Darunavir has the highest barrier to resistance of the currently used options, requiring multiple simultaneous mutations before it loses potency. This is one reason it remains a cornerstone of treatment regimens, including in cases where other drugs have already failed. Resistance testing through blood samples is standard practice before starting or switching therapy, allowing doctors to choose drugs the patient’s specific viral population is still susceptible to.